StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
116
This year
5
Publishing Date
2023 - 10 - 12
2
2023 - 06 - 26
3
2022 - 11 - 04
2
2022 - 06 - 08
2
2022 - 03 - 29
1
2022 - 03 - 16
2
2022 - 03 - 10
1
2022 - 03 - 01
1
2022 - 02 - 24
1
2022 - 02 - 23
1
2022 - 02 - 16
1
2022 - 02 - 10
1
2022 - 02 - 01
1
2022 - 01 - 27
1
2021 - 12 - 21
1
2021 - 12 - 12
1
2021 - 11 - 16
1
2021 - 11 - 15
1
2021 - 11 - 12
1
2021 - 10 - 28
1
2021 - 10 - 19
1
2021 - 10 - 14
2
2021 - 09 - 30
1
2021 - 09 - 28
2
2021 - 09 - 27
2
2021 - 09 - 24
1
2021 - 09 - 08
1
2021 - 09 - 01
1
2021 - 08 - 27
1
2021 - 08 - 16
1
2021 - 08 - 05
1
2021 - 07 - 21
1
2021 - 07 - 15
1
2021 - 07 - 06
1
2021 - 06 - 29
2
2021 - 06 - 22
1
2021 - 06 - 18
1
2021 - 06 - 17
2
2021 - 06 - 16
1
2021 - 06 - 15
2
2021 - 06 - 08
1
2021 - 06 - 07
3
2021 - 06 - 03
1
2021 - 05 - 25
1
2021 - 05 - 20
1
2021 - 05 - 04
1
2021 - 04 - 29
1
2021 - 04 - 20
1
2021 - 04 - 13
1
2021 - 03 - 29
1
2021 - 03 - 17
1
2021 - 03 - 11
1
2021 - 03 - 10
2
2021 - 03 - 03
1
2021 - 02 - 17
1
2021 - 02 - 11
1
2021 - 01 - 27
1
2021 - 01 - 21
1
2020 - 12 - 21
1
2020 - 12 - 11
1
Sector
Commercial services
2
Communications
1
Health services
2
Health technology
116
Manufacturing
1
Tags
Agreement
25
Alliances
39
Alzheimer's
23
Alzheimer’s
23
Antibody
51
Approval
46
Biomidwest
40
Biopharma
36
Biotech-bay
24
Biotechnology
25
Cancer
139
China
47
Chinese
28
Clinical-trials-phase-iii
32
Collaboration
71
Companies
51
Conference
76
Covid
62
Covid-19
49
Designation
22
Diabetes
57
Disease
89
Drug
105
Earnings
45
Events
32
Expected
24
Fda
71
Financial
65
Financial results
42
Global
149
Growth
108
Health
30
Heart
23
Insulin
37
Iot
23
License
26
Market
306
Meeting
27
Money
34
N/a
1122
Obesity
28
People
70
Pharma
35
Pharmaceutical
24
Phase 1
24
Phase 2
34
Phase 3
47
Positive
30
Report
141
Research
148
Results
203
Risk
24
Study
74
Technology
27
Therapeutics
139
Therapy
88
Tirzepatide
24
Treatment
175
Trial
116
Update
33
Entities
Abcellera biologics inc
2
Ac immune sa
2
Akouos, inc.
1
Alnylam pharmaceuticals, inc.
6
Alx oncology holdings inc.
2
Anavex life sciences corp.
1
Aptinyx inc.
1
Astrazeneca plc
1
Athenex, inc.
1
Atreca, inc.
1
Aveo pharmaceuticals, inc.
2
Biogen inc.
1
Biovie inc.
1
Curis, inc.
1
Cyteir therapeutics inc
1
Denali therapeutics inc.
1
Eli lilly and company
116
Erasca inc
2
Glaxosmithkline plc
2
Icon plc
3
Immunogen, inc.
1
Incyte corporation
18
Iqvia holdings, inc.
1
Johnson & johnson
3
Lantheus holdings, inc.
1
Leap therapeutics, inc.
1
Ligand pharmaceuticals incorporated
3
Nektar therapeutics
1
Novo nordisk a/s
9
Omeros corporation
1
Orange
1
Point biopharma global inc
1
Quanterix corporation
1
Rigel pharmaceuticals, inc.
6
Sanofi
13
Seagen inc.
1
Sorrento therapeutics, inc.
1
Takeda pharmaceutical company limited
1
Vanda pharmaceuticals inc.
1
Veru inc.
5
Vir biotechnology, inc.
2
Vistagen therapeutics, inc.
1
Symbols
ABB
72
ABBV
32
ABLZF
31
ACHV
21
AIMC
23
ALDX
32
ALPMF
22
ALPMY
22
ARQT
22
ARVL
21
ATHE
26
ATNM
25
AVXL
21
AZN
52
BGNE
23
BIVI
23
BMY
48
BTAI
26
CLSD
22
CNHI
69
CYTK
24
DVAX
23
ENLV
25
EXEL
28
FBIO
29
FDMT
21
FNCTF
66
GIC
37
GILD
23
GTES
25
HCM
22
HON
53
HZNP
35
ICLR
26
IMAB
21
IMMP
25
IMMX
23
IMUX
21
INCY
28
JCI
22
JNJ
99
LLY
116
MBRX
30
MRK
45
NVCR
23
NVO
32
NVS
25
OCGN
23
PDSB
23
PFE
47
PSTV
29
REGN
30
RGNX
27
SLS
23
SNY
166
SNYNF
121
SRNE
33
STAG
32
TAK
36
TMO
28
Exchanges
Nasdaq
64
Nyse
116
Crawled Date
2023 - 10 - 12
2
2023 - 06 - 26
3
2022 - 11 - 04
2
2022 - 06 - 08
2
2022 - 05 - 26
1
2022 - 05 - 09
1
2022 - 03 - 29
1
2022 - 03 - 16
2
2022 - 03 - 10
1
2022 - 03 - 01
1
2022 - 02 - 24
2
2022 - 02 - 16
1
2022 - 02 - 10
1
2022 - 02 - 01
1
2022 - 01 - 27
1
2021 - 12 - 21
1
2021 - 12 - 12
1
2021 - 11 - 16
1
2021 - 11 - 15
1
2021 - 11 - 12
1
2021 - 10 - 28
1
2021 - 10 - 19
1
2021 - 10 - 14
2
2021 - 09 - 30
1
2021 - 09 - 28
2
2021 - 09 - 27
2
2021 - 09 - 24
1
2021 - 09 - 08
1
2021 - 09 - 01
1
2021 - 08 - 27
1
2021 - 08 - 16
1
2021 - 08 - 05
1
2021 - 07 - 21
1
2021 - 07 - 15
1
2021 - 07 - 06
1
2021 - 06 - 29
2
2021 - 06 - 22
1
2021 - 06 - 18
3
2021 - 06 - 16
1
2021 - 06 - 15
2
2021 - 06 - 08
1
2021 - 06 - 07
3
2021 - 06 - 03
1
2021 - 05 - 25
1
2021 - 05 - 20
1
2021 - 05 - 04
1
2021 - 04 - 29
1
2021 - 04 - 20
1
2021 - 04 - 13
1
2021 - 03 - 29
1
2021 - 03 - 17
1
2021 - 03 - 11
1
2021 - 03 - 10
2
2021 - 03 - 03
1
2021 - 02 - 17
1
2021 - 02 - 11
1
2021 - 01 - 27
1
2021 - 01 - 21
1
2020 - 12 - 21
1
2020 - 12 - 11
1
Crawled Time
00:00
9
01:00
14
02:00
1
05:00
1
06:00
1
07:00
4
08:00
2
10:00
1
11:00
5
12:00
8
12:09
1
12:11
1
12:15
4
12:20
2
12:30
3
12:39
1
13:00
6
13:01
1
14:00
6
14:15
2
14:30
2
15:00
7
15:30
2
16:00
7
16:20
2
17:00
6
18:00
3
19:00
2
19:11
1
20:00
3
21:00
2
22:00
3
23:00
3
Source
investor.aveooncology.com
1
www.biospace.com
56
www.clarivate.com
1
www.globenewswire.com
11
www.prnewswire.com
47
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Trial
symbols :
Lly
save search
Blacksmith Medicines Announces $3.3M in Funding from NIAID to Support Clinical Trial Manufacturing of Novel Antibiotic
Published:
2024-02-21
(Crawled : 15:00)
- prnewswire.com
CYT
|
$3.02
2.65%
1M
|
Manufacturing
|
-2.58%
|
O:
-0.32%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
-0.46%
|
O:
-2.33%
H:
1.55%
C:
1.06%
trial
funding
Vanda Pharmaceuticals announces the publication of an article on The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial
Published:
2024-01-25
(Crawled : 22:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
18.7%
|
O:
-1.0%
H:
0.84%
C:
0.04%
VNDA
|
$4.56
-1.51%
-1.31%
1.1M
|
Health Technology
|
24.25%
|
O:
2.72%
H:
0.53%
C:
0.53%
publication
pharmaceuticals
trial
diabetic
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published:
2024-01-23
(Crawled : 17:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
19.23%
|
O:
-0.51%
H:
0.37%
C:
0.32%
genetic
association
positive
research
meeting
trial
therapy
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Published:
2024-01-16
(Crawled : 12:30)
- globenewswire.com
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
17.0%
|
O:
0.15%
H:
0.59%
C:
-1.45%
erbitux
first
cell
trial
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Published:
2024-01-09
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
20.16%
|
O:
0.65%
H:
0.69%
C:
-0.73%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-7.93%
|
O:
0.74%
H:
0.0%
C:
0.0%
INCY
|
$51.74
0.17%
0.14%
1.6M
|
Health Technology
|
-21.39%
|
O:
0.0%
H:
0.53%
C:
-2.19%
obesity
first
chinese
key
trial
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published:
2023-12-28
(Crawled : 00:00)
- prnewswire.com
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-5.57%
|
O:
0.28%
H:
0.0%
C:
-1.32%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
29.35%
|
O:
0.08%
H:
0.81%
C:
-0.19%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-3.75%
|
O:
0.52%
H:
0.72%
C:
-0.34%
INCY
|
$51.74
0.17%
0.14%
1.6M
|
Health Technology
|
-17.45%
|
O:
0.35%
H:
1.07%
C:
-0.27%
candidate
tumors
collaboration
trial
advanced
china
therapy
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Published:
2023-12-18
(Crawled : 12:30)
- globenewswire.com
PNT
|
$13.68
2.63%
0.15%
0
|
|
-9.84%
|
O:
-10.09%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
32.59%
|
O:
1.61%
H:
1.14%
C:
0.57%
LNTH
|
$65.21
1.24%
1.2%
580K
|
Health Technology
|
-14.24%
|
O:
-19.87%
H:
5.04%
C:
-8.75%
positive
cancer
biopharma
topline
trial
results
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
Published:
2023-12-15
(Crawled : 12:30)
- globenewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-5.36%
|
O:
-0.39%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
26.71%
|
O:
-4.44%
H:
0.0%
C:
0.0%
ACIU
|
$2.37
-0.42%
-2.15%
320K
|
Health Technology
|
-36.12%
|
O:
-1.62%
H:
9.04%
C:
7.4%
disease
active
alzheimer’s
immunotherapy
trial
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
Published:
2023-12-11
(Crawled : 20:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
27.68%
|
O:
1.61%
H:
0.0%
C:
0.0%
LGND
|
$71.0
1.59%
1.38%
110K
|
Health Technology
|
14.85%
|
O:
0.29%
H:
1.26%
C:
0.87%
publication
pharmaceuticals
trial
results
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
Published:
2023-10-26
(Crawled : 00:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
28.26%
|
O:
-1.68%
H:
0.0%
C:
0.0%
bge-105
agonist
treatment
collaboration
trial
tirzepatide
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
Published:
2023-10-24
(Crawled : 14:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
28.4%
|
O:
-0.84%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-8.74%
|
O:
0.77%
H:
0.0%
C:
0.0%
thn391
treatment
dementia
trial
potential
results
Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
Published:
2023-10-12
(Crawled : 15:30)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-14.67%
|
O:
-0.97%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-6.66%
|
O:
-1.87%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
24.27%
|
O:
0.54%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-13.48%
|
O:
0.14%
H:
0.0%
C:
0.0%
trial
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial
Published:
2023-10-12
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
24.27%
|
O:
0.54%
H:
0.0%
C:
0.0%
disease
trial
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published:
2023-10-03
(Crawled : 10:00)
- globenewswire.com
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
40.32%
|
O:
0.19%
H:
0.0%
C:
0.0%
ALXO
M
|
$16.22
4.65%
4.56%
440K
|
Commercial Services
|
237.21%
|
O:
68.19%
H:
2.84%
C:
-7.17%
aspen-06
positive
cancer
treatment
trial
results
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
Published:
2023-09-26
(Crawled : 13:00)
- globenewswire.com
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
36.2%
|
O:
-0.17%
H:
0.0%
C:
0.0%
VERU
|
$1.32
3.53%
3.77%
1.5M
|
Health Technology
|
56.75%
|
O:
5.69%
H:
3.37%
C:
-10.11%
fda
sabizabulin
respiratory
trial
agreement
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors
Published:
2023-09-19
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
31.67%
|
O:
0.06%
H:
1.19%
C:
0.58%
bbi-355
verzenio
tumors
collaboration
trial
agreement
ADDF Statement on New Results from Donanemab's TRAILBLAZER-ALZ 2 Trial
Published:
2023-07-17
(Crawled : 16:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
67.36%
|
O:
-0.0%
H:
0.26%
C:
-0.51%
trial
results
New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Published:
2023-07-06
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
61.52%
|
O:
-0.55%
H:
0.97%
C:
0.02%
leukemia
trial
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
Published:
2023-06-26
(Crawled : 21:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
66.14%
|
O:
2.15%
H:
1.18%
C:
0.43%
SRNE
|
$0.02
33.33%
-8.85%
97K
|
Health Technology
|
-97.13%
|
O:
-1.0%
H:
4.2%
C:
1.3%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
16.38%
|
O:
0.82%
H:
0.02%
C:
-0.85%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-11.28%
|
O:
0.17%
H:
0.0%
C:
0.0%
OMER
|
$3.04
-1.62%
-1.64%
250K
|
Health Technology
|
-43.7%
|
O:
0.19%
H:
2.22%
C:
1.76%
IMGN
|
News
|
$31.23
0.03%
49M
|
Health Technology
|
65.12%
|
O:
0.58%
H:
2.57%
C:
0.26%
companies
pipeline
trial
Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics
Published:
2023-06-26
(Crawled : 18:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
63.94%
|
O:
1.4%
H:
0.0%
C:
-2.69%
LGND
|
$71.0
1.59%
1.38%
110K
|
Health Technology
|
-2.86%
|
O:
-0.3%
H:
1.85%
C:
-0.84%
cancer
pharmaceuticals
trial
← Previous
1
2
3
4
5
6
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4253
179.25%
64.77%
210M
|
Consumer Services
BOF
|
$2.08
77.78%
41.21%
110M
|
ILAG
|
$0.54
12.27%
40.62%
3.7M
|
LICN
|
$0.999
78.39%
40.49%
15M
|
AMST
|
$3.4
70.0%
39.58%
70M
|
Technology Services
MTC
|
$3.6
60.71%
38.04%
9.1M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.458
14.5%
30.92%
91K
|
Health Services
WHLM
|
$6.25
35.87%
28.46%
700K
|
Commercial Services
MULN
|
News
|
$3.77
38.1%
27.78%
13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.